UNITED THERAPEUTICS Corp
UNITED THERAPEUTICS Corp is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
UNITED THERAPEUTICS Corp generates cash from operations, so a burn-based runway figure does not apply.
Across 74 concluded trials, 58% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 4, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2026 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | Trial Milestone | Phase 3 |
| November 15, 2027 | Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | Trial Milestone | Phase 3 |
| October 15, 2028 | Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD | Trial Milestone | Phase 1/Phase 2 |
| November 15, 2029 | Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD | Trial Milestone | Phase 1/Phase 2 |
| December 15, 2029 | Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease | Trial Milestone | Phase 3 |
Track UTHR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open UTHR in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.